RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
  Anorexia Nervosa
  Anxiety
  Bulimia
  CFS
  Child Psychiatry
  Depression
  Forensic Psychiatry
  Learning-Disabilities
  Mood Disorders
  Neuropsychiatry
  Peri-Natal Psychiatry
  Personality Disorders
  Psychology
  Psychoses
  Psychotherapy
  Sleep Disorders
  Substance Abuse
  Suicide
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Anorexia Nervosa Channel

subscribe to Anorexia Nervosa newsletter
Latest Research : Psychiatry : Anorexia Nervosa

   EMAIL   |   PRINT
Antidepressants does not decrease risk of relapse in anorexia nervosa

Jun 14, 2006 - 7:42:00 PM , Reviewed by: Ankush Vidyarthi
The most conservative analysis of time-to-relapse found no significant difference between the fluoxetine and placebo groups in time-to-relapse. At 52 weeks, 45 percent of the placebo group and 43 percent of the fluoxetine group had not relapsed.

 
[RxPG] Use of the anti-depressant fluoxetine did not help patients with anorexia nervosa who had restored their body weight maintain that weight or reduce their risk of relapse, according to a study in the June 14 issue of JAMA.

Anorexia nervosa is an eating disorder primarily affecting young women and marked by an extreme fear of becoming overweight that leads to excessive dieting to the point of serious ill-health and sometimes death. It is a serious psychiatric illness with a lifetime death rate arguably as high as that associated with any psychiatric illness, according to background information in the article. A major contributor to the poor prognosis of this illness is the high rate of relapse, with 30 to 50 percent of patients requiring rehospitalization within 1 year of discharge after successful weight restoration. This has prompted interest in interventions aimed at preventing relapse following weight restoration. A substantial number of patients with anorexia nervosa receive antidepressant medications. Fluoxetine was initially marketed under the brand name of Prozac.

B. Timothy Walsh, M.D., of New York State Psychiatric Institute/Columbia University Medical Center, New York, and colleagues compared fluoxetine with placebo to determine the rate of relapse and behavioral recovery following initial treatment for anorexia nervosa. The trial included 93 patients with anorexia nervosa who had received intensive inpatient or day-program treatment and regained weight to a minimum body mass index (BMI) of 19.0. Participants were then randomly assigned to receive fluoxetine (n = 49) or placebo (n = 44) and were treated for up to 1 year as outpatients.

The researchers found that similar percentages of patients assigned to fluoxetine and to placebo maintained a BMI of at least 18.5 and remained in the study for 52 weeks (fluoxetine: 26.5 percent; placebo: 31.5 percent). The most conservative analysis of time-to-relapse found no significant difference between the fluoxetine and placebo groups in time-to-relapse. At 52 weeks, 45 percent of the placebo group and 43 percent of the fluoxetine group had not relapsed.

"The current study has implications for both clinical practice and research. The present findings, coupled with those of previously published studies, indicate that the common practice of prescribing antidepressant medication is unlikely to provide substantial benefit for most patients with anorexia nervosa, either when they are underweight or immediately upon weight restoration. These data imply that therapeutic efforts would be better devoted to psychological and behavioral interventions for which there is some, albeit modest, evidence of efficacy," the authors write. "Future research on the utility of novel psychological treatments and innovative psychotropic and nonpsychotropic medications is obviously needed."

In an accompanying editorial, Scott J. Crow, M.D., of the University of Minnesota, Minneapolis, comments on the findings of the study examining the use of fluoxetine for anorexia nervosa.

"The study by Walsh et al is an important contribution that addresses a major gap in research on anorexia nervosa and provides vital information about a fairly common treatment practice for this illness. Unfortunately, it appears that fluoxetine provides no benefit in the relapse prevention treatment of anorexia nervosa. Despite a prevalence rate similar to many other psychiatric illnesses, and particularly in light of the high mortality associated with anorexia nervosa, there is a serious underrepresentation of anorexia nervosa in biomedical research. Much more information is needed on the treatment of individuals with anorexia nervosa while they are at low weight. In addition, strategies must be developed to help individuals who recover to stay in recovery."



Publication: June 14 issue of JAMA; JAMA. 2006;295:2605-2612.
On the web: pubs.ama-assn.org 

Advertise in this space for $10 per month. Contact us today.


Related Anorexia Nervosa News
Antidepressants does not decrease risk of relapse in anorexia nervosa
Bulimia-type anorexia nervosa shows increased serotonin binding

Subscribe to Anorexia Nervosa Newsletter

Enter your email address:


 Additional information about the news article
This study was supported in part by grants from the National Institutes of Health. Eli Lilly supplied fluoxetine and placebo.

Dr. Crow reports having received research support from Eli Lilly, Abbott Laboratories, GlaxoSmithKline, Ortho McNeil Pharmaceuticals, Pfizer, and Bristol-Myers Squibb; consultant fees from Ortho McNeil Pharmaceuticals; and honoraria from Pfizer.
 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)